文献速递白血病

FOXO1的严密调控对维持B细胞前体急性淋巴细胞白血病至关重要

Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2018-04-05

该研究在B细胞前体急性淋巴细胞白血病(BCP-ALL)细胞系和患者来源的儿童ALL异种移植模型中,通过遗传学和药理学方法失活FOXO1,发现其产生强抗白血病效应并伴随CCND3下调;CCND3过表达可保护细胞系免受FOXO1失活诱导的生长停滞和凋亡;药理学抑制FOXO1在多个原代患者来源的儿童ALL异种移植模型中显示抗白血病活性,减少造血、淋巴和中枢神经系统器官区室的白血病负荷,并最终在临床前体内模型中延长生存且无白血病复发。结果提示抑制FOXO1可能是治疗BCP-ALL的可行方法。

要点

  • 遗传学和药理学失活FOXO1在BCP-ALL细胞系中产生强抗白血病效应,与CCND3下调相关。
  • CCND3表达对BCP-ALL生存至关重要,过表达可保护细胞系免受FOXO1失活诱导的生长停滞和凋亡。
  • 药理学抑制FOXO1在多个原代患者来源的儿童ALL异种移植模型中显示抗白血病活性,减少造血、淋巴和中枢神经系统区室的白血病负荷,并延长生存且无复发。

核心结论

  • 严密调控的FOXO1活性对维持B细胞前体急性淋巴细胞白血病(BCP-ALL)至关重要,抑制FOXO1可能是治疗BCP-ALL的可行方法。

研究设计与样本

  • 研究使用BCP-ALL细胞系和原代患者来源的儿童ALL异种移植模型,进行遗传学和药理学失活FOXO1的实验。

主要发现

  • 在BCP-ALL细胞系中遗传学和药理学失活FOXO1产生强抗白血病效应,伴随CCND3下调。
  • CCND3表达对BCP-ALL生存至关重要,过表达CCND3可保护BCP-ALL细胞系免受FOXO1失活诱导的生长停滞和凋亡。
  • 药理学抑制FOXO1在多个原代患者来源的儿童ALL异种移植模型中显示抗白血病活性,有效减少造血、淋巴和中枢神经系统器官区室的白血病负荷。
  • 在BCP-ALL临床前体内模型中,药理学抑制FOXO1最终导致生存延长且无白血病复发。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The FOXO1 transcription factor plays an essential role in the regulation of proliferation and survival programs at early stages of B-cell differentiation. Here, we show that tightly regulated FOXO1 activity is essential for maintenance of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Genetic and pharmacological inactivation of FOXO1 in BCP-ALL cell lines produced a strong antileukemic effect associated with CCND3 downregulation. Moreover, we demonstrated that CCND3 expression is critical for BCP-ALL survival and that overexpression of CCND3 protected BCP-ALL cell lines from growth arrest and apoptosis induced by FOXO1 inactivation. Most importantly, pharmacological inhibition of FOXO1 showed antileukemia activity on several primary, patient-derived, pediatric ALL xenografts with effective leukemia reduction in the hematopoietic, lymphoid, and central nervous system organ compartments, ultimately leading to prolonged survival without leukemia reoccurrence in a preclinical in vivo model of BCP-ALL. These results suggest that repression of FOXO1 might be a feasible approach for the treatment of BCP-ALL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Wang F, Demir S, Gehringer F, et al. Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia. Blood. 2018. PMID: 29622548. doi:10.1182/blood-2017-10-813576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。